|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hamdy FC, Donovan JL, Lane JA, Mason M,
Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, et
al: 10-Year outcomes after monitoring, surgery, or radiotherapy for
localized prostate cancer. N Engl J Med. 375:1415–1424. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weckermann D, Polzer B, Ragg T, Blana A,
Schlimok G, Arnholdt H, Bertz S, Harzmann R and Klein CA:
Perioperative activation of disseminated tumor cells in bone marrow
of patients with prostate cancer. J Clin Oncol. 27:1549–1556. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
National Cancer Institute, . SEER Cancer
Stat Facts: Prostate Cancer. 2020.http://seer.cancer.gov/statfacts/html/prost.htmlNovember
14–2020
|
|
5
|
Sweeney CJ, Chen YH, Carducci M, Liu G,
Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et
al: Chemohormonal therapy in metastatic hormone-sensitive prostate
cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wadosky KM and Koochekpour S: Molecular
mechanisms underlying resistance to androgen deprivation therapy in
prostate cancer. Oncotarget. 7:64447–64470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sumanasuriya S and Bono JD: Treatment of
advanced prostate cancer-A review of current therapies and future
promise. Cold Spring Harb Perspect Med. 8:a0306352018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pezaro C, Omlin A, Lorente D, Rodrigues
DN, Ferraldeschi R, Bianchini D, Mukherji D, Riisnaes R, Altavilla
A, Crespo M, et al: Visceral disease in castration-resistant
prostate cancer. Eur Urol. 65:270–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shiirevnyamba A, Takahashi T, Shan H,
Ogawa H, Yano S, Kanayama H, Izumi K and Uehara H: Enhancement of
osteoclastogenic activity in osteolytic prostate cancer cells by
physical contact with osteoblasts. Br J Cancer. 104:505–513. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Antunes J, Gaspar VM, Ferreira L, Monteiro
M, Henrique R, Jerónimo C and Mano JF: In-air production of 3D
co-culture tumor spheroid hydrogels for expedited drug screening.
Acta Biomater. 94:392–409. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ryan CJ, Smith MR, Fizazi K, Saad F,
Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small
EJ, et al: Abiraterone acetate plus prednisone versus placebo plus
prednisone in chemotherapy-naive men with metastatic
castration-resistant prostate cancer (COU-AA-302): Final overall
survival analysis of a randomised, double-blind, placebo-controlled
phase 3 study. Lancet Oncol. 16:152–160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Z, Alyamani M, Li J, Rogacki K, Abazeed
M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ and Sharifi N:
Redirecting abiraterone metabolism to fine-tune prostate cancer
anti-androgen therapy. Nature. 533:547–551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Andriole GL, Bostwick DG, Brawley OW,
Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL,
Teloken C, Tindall DJ, et al: Effect of dutasteride on the risk of
prostate cancer. N Engl J Med. 362:1192–1202. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsuyama H, Shiota M, Tashiro K, Kanji H,
Horiyama S, Eto M, Egawa S, Haginaka J and Inoue R: Phase II study
of the efficacy of abiraterone acetate with dutasteride for
castration resistant prostate cancer. J Clin Oncol. 39:112. 2021.
View Article : Google Scholar
|
|
17
|
Horoszewicz JS, Leong SS, Kawinski E, Karr
JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LNCaP model of
human prostatic carcinoma. Cancer Res. 43:1809–1818.
1983.PubMed/NCBI
|
|
18
|
Cai C, Chen S, Ng P, Bubley GJ, Nelson PS,
Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, et al:
Intratumoral de novo steroid synthesis activates androgen receptor
in castration-resistant prostate cancer and is upregulated by
treatment with CYP17A1 inhibitors. Cancer Res. 71:6503–6513. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rajendran D, Hussain A, Yip D, Parekh A,
Shrirao A and Cho CH: Long-term liver-specific functions of
hepatocytes in electrospun chitosan nanofiber scaffolds coated with
fibronectin. J Biomed Mater Res A. 105:2119–2128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hussain A, Collins G, Yip D and Cho CH:
Functional 3-D cardiac co-culture model using bioactive chitosan
nanofiber scaffolds. Biotechnol Bioeng. 110:637–647. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ho MH, Liao MH, Lin YL, Lai CH, Lin PI and
Chen RM: Improving effects of chitosan nanofiber scaffolds on
osteoblast proliferation and maturation. Int J Nanomedicine.
9:4293–4304. 2014.PubMed/NCBI
|
|
22
|
Kimura Y, Matsugaki A, Sekita A and Nakano
T: Alteration of osteoblast arrangement via direct attack by cancer
cells: New insights into bone metastasis. Sci Rep. 7:448242017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kingsley LA, Fournier PG, Chirgwin JM and
Guise TA: Molecular biology of bone metastasis. Mol Cancer Ther.
6:2609–2617. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang N, Docherty FE, Brown HK, Reeves KJ,
Fowles AC, Ottewell PD, Dear TN, Holen I, Croucher PI and Eaton CL:
Prostate cancer cells preferentially home to osteoblast-rich areas
in the early stages of bone metastasis: Evidence from in vivo
models. J Bone Miner Res. 29:2688–2696. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Klein CA: Selection and adaptation during
metastatic cancer progression. Nature. 501:365–372. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guise TA, Mohammad KS, Clines G, Stebbins
EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L
and Chirgwin JM: Basic mechanisms responsible for osteolytic and
osteoblastic bone metastases. Clin Cancer Res. 12 (Suppl
1):6213S–6216S. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weilbaecher KN, Guise TA and McCauley LK:
Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiechi A, Waning DL, Stayrook KR, Buijs
JT, Guise TA and Mohammad KS: Role of TGF-β in breast cancer bone
metastases. Adv Biosci Biotechnol. 4:15–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pickup M, Novitskiy S and Moses HL: The
roles of TGFβ in the tumour microenvironment. Nat Rev Cancer.
13:788–799. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Juárez P and Guise TA: TGF-β in cancer and
bone: Implications for treatment of bone metastases. Bone.
48:23–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Montanari M, Rossetti S, Cavaliere C,
D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E,
Iovane G, Piscitelli R, et al: Epithelial-mesenchymal transition in
prostate cancer: An overview. Oncotarget. 8:35376–35389. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakazawa M and Kyprianou N:
Epithelial-mesenchymal-transition regulators in prostate cancer:
Androgens and beyond. J Steroid Biochem Mol Biol. 166:84–90. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shiota M, Itsumi M, Takeuchi A, Imada K,
Yokomizo A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y and
Naito S: Crosstalk between epithelial-mesenchymal transition and
castration resistance mediated by Twist1/AR signaling in prostate
cancer. Endocr Relat Cancer. 22:889–900. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fizazi K, Yang J, Peleg S, Sikes CR,
Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis
CJ, et al: Prostate cancer cells-osteoblast interaction shifts
expression of growth/survival-related genes in prostate cancer and
reduces expression of osteoprotegerin in osteoblasts. Clin Cancer
Res. 9:2587–2597. 2003.PubMed/NCBI
|
|
35
|
Xu K, Wang Z, Copland JA, Chakrabarti R
and Florczyk SJ: 3D porous chitosan-chondroitin sulfate scaffolds
promote epithelial to mesenchymal transition in prostate cancer
cells. Biomaterials. 254:1201262020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu K, Ganapathy K, Andl T, Wang Z, Copland
JA, Chakrabarti R and Florczyk SJ: 3D porous chitosan-alginate
scaffold stiffness promotes differential responses in prostate
cancer cell lines. Biomaterials. 217:1193112019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang K, Kievit FM, Florczyk SJ, Stephen ZR
and Zhang M: 3D porous chitosan-alginate scaffolds as an in vitro
model for evaluating nanoparticle-mediated tumor targeting and gene
delivery to prostate cancer. Biomacromolecules. 16:3362–3372. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Elbadawy M, Abugomaa A, Yamawaki H, Usui T
and Sasaki K: Development of prostate cancer organoid culture
models in basic medicine and translational research. Cancers
(Basel). 12:7772020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bartucci M, Ferrari AC, Kim IY, Ploss A,
Yarmush M and Sabaawy HE: Personalized medicine approaches in
prostate cancer employing patient derived 3D organoids and
humanized mice. Front Cell Dev Biol. 4:642016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kuchimaru T, Kataoka N, Nakagawa K,
Isozaki T, Miyabara H, Minegishi M, Kadonosono T and Kizaka-Kondoh
S: A reliable murine model of bone metastasis by injecting cancer
cells through caudal arteries. Nat Commun. 30:29812018. View Article : Google Scholar : PubMed/NCBI
|
